tiprankstipranks
Trending News
More News >

Theravance Biopharma Settles Patent Litigation with Eugia

Story Highlights
Theravance Biopharma Settles Patent Litigation with Eugia

Confident Investing Starts Here:

Theravance Biopharma ( (TBPH) ) has issued an update.

On June 5, 2025, Theravance Biopharma and Mylan entered into a Settlement Agreement with Eugia Pharma to resolve ongoing patent litigation concerning the YUPELRI® inhalation solution. The agreement allows Eugia to manufacture and market a generic version of YUPELRI® in the U.S. starting April 23, 2039, pending review by the U.S. Department of Justice and the Federal Trade Commission, while litigation continues against other ANDA filers.

The most recent analyst rating on (TBPH) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Spark’s Take on TBPH Stock

According to Spark, TipRanks’ AI Analyst, TBPH is a Neutral.

Theravance Biopharma’s stock score reflects a mix of financial stabilization and positive technical momentum, offset by valuation concerns due to unprofitability. The company shows potential for growth with improved cash flow and strategic advancements, but profitability and valuation issues need addressing.

To see Spark’s full report on TBPH stock, click here.

More about Theravance Biopharma

Theravance Biopharma operates in the pharmaceutical industry, focusing on the development and commercialization of respiratory medicines, including YUPELRI® (revefenacin) inhalation solution.

Average Trading Volume: 274,315

Technical Sentiment Signal: Buy

Current Market Cap: $550.5M

For detailed information about TBPH stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App